Acute Lymphoblastic Leukemia (ALL) Therapeutics Market, by Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy, Bone Marrow Transplantation, Others), by Disease Type (Acute T-Lymphoblastic Leukemia and Acute B-Lymphoblastic Leukemia), by Administration Route (Oral And Parenteral), By End-user (Hospitals, Clinics & Diagnostic Centers, Others) -Global Industry Insights, Trends and Forecast, 2017-2025

Created On: Jun-2018
Report ID: IR39
Format: PDF

Market Introduction

Acute lymphoblastic leukemia is cancer that occurs in the white blood cells, also known as lymphocytes in the bone marrow. It is considered to be a malignant disease where early precursor lymphoid cells escalate and replace the hematopoietic cells of the bone marrow. Acute lymphoblastic leukemia is commonly found in children. In case of such a disease, there is an overproduction of lymphoblasts in the bone marrow which multiplies on a continuous basis thereby damaging the bone marrow by restricting the production of red blood cells and platelet count. Acute lymphoblastic leukemia results in significant decline in red blood and white blood cells and platelet counts, thereby resulting in anemia, various types of infections and profuse bleeding. This type of cancer gradually affects the brain and the spinal cord as well.

The market for acute lymphoblastic leukemia therapeutics market is expected to witness considerable growth during the forecast period on account of increasing awareness regarding cancer treatment, innovative drug formulations, rising per capita healthcare spending and technological advancements in the field of healthcare and various others.

Market Dynamics

Rising cases of acute lymphoblastic leukemia (ALL) are one of the key factors pushing the market growth of acute lymphoblastic leukemia therapeutics market. According to Insights and Reports, in 2017 more than 5,800 cases of ALL were diagnosed in the U.S. and the same were more prevalent in males as compared to females. Further, more than 1,300 deaths were recorded in the country in the same year as well. ALL is more prevalent in children aged below 5 and adults aged above 50. However, adults are more susceptible to deaths due to ALL. Further, Europe witness approximately 7,500 cases of ALL, and the same is most prevalent among children. About 10,000 cases of ALL are diagnosed each year among the adult population in Europe. These factors are largely responsible for the growth of the market in these regions at present.

However, the acute lymphoblastic leukemia therapeutics market consists of fewer key players at present and is an excellent opportunity for the new players to penetrate this market in the future. Further, rising aging population is another opportunity for the growth of the ALL therapeutics market in the coming years. According to the World Health Organization, the percentage of the geriatric population at the global level is expected to cross the 15% mark of the total population by 2050.

Market Segmentation and Analysis

Based on treatment type, the market for acute lymphoblastic leukemia therapeutics has been classified into chemotherapy, immunotherapy, radiation therapy, and bone marrow transplantation among others. Chemotherapy has been further classified into corticosteroids, colony-stimulating factors, tyrosine kinase inhibitors and various others. Chemotherapy is expected to lead the market throughout the forecast period on account of high availability of a varied range of chemotherapeutic agents for cancer treatment and upcoming innovations in the field of chemotherapy.

Based on disease type, the market has been segmented into acute T-lymphoblastic leukemia and acute B-lymphoblastic leukemia. Based on the administration route, the market for ALL therapeutics is classified into oral and parenteral.

Based on end-user, the ALL therapeutics market is classified into hospitals, clinics & diagnostic centers and others.

Geographical Outlook

North America and Europe dominated the acute lymphoblastic leukemia therapeutics market in 2016 and is expected to show the same trend throughout the forecast period. Presence of established healthcare facilities in these regions are the key factors pushing the growth of the market in these regions. U.S., Germany, U.K., France, and Canada are the major contributors to the growth of the ALL therapeutics market in these regions. Large-scale product developments by major companies dealing in this industry is another factor pushing the growth of the market.

Asia Pacific is expected to be the fastest growing market for acute lymphoblastic leukemia therapeutics market, with India and China leading the growth of the market in the region. High population is a key factor driving the growth of the industry at present. Further, rising birth rates and the abolishment of the one-child policy in China are some of the other major factors fuelling the market growth of the ALL therapeutics market in Asia Pacific. Moreover, rising aging population is also driving the growth of the market at present

Competitive Landscape

Some of the key players operating in the field of acute lymphoblastic leukemia therapeutics market include Celgene Corporation, GlaxoSmithKline Plc, Roche Holding A.G., and Bristol-Myers Squibb among others.

Our Research Approach Includes
  •  Market Outlining
  •  Framing discussion guide
  •  Data Validation
  • Data Analysis
  •  Re-Validation and Finalization of Data
  •  Report Insights and Publishing
Our Research Approach Includes
  •  Market Outlining
  •  Framing discussion guide
  •  Data Validation
  • Data Analysis
  •  Re-Validation and Finalization of Data
  •  Report Insights and Publishing
Reach Out to us